Spectrum Pharmaceuticals, Inc

This trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only pat…

This study tested a drug called poziotinib in 648 people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 mutations). The goal was to see if the drug could shrink tumors. The study was stopped early, but results showed some patients…